-
公开(公告)号:EP4431083A1
公开(公告)日:2024-09-18
申请号:EP23382249.3
申请日:2023-03-16
申请人: Adalvo Limited
IPC分类号: A61K9/00 , A61K31/7042 , A61K47/40 , A61P31/04
CPC分类号: A61K9/0019 , A61K47/40 , A61P31/04 , A61K31/7042
摘要: The present invention relates to a pharmaceutical formulation containing dalbavancin or a pharmaceutically acceptable salt thereof, a cyclodextrin and water. The novel fonnulations have a significantly increased stability over known dalbavancin formulations.
-
2.
公开(公告)号:EP4426278A1
公开(公告)日:2024-09-11
申请号:EP22889566.0
申请日:2022-10-03
申请人: TyrNovo Ltd.
发明人: REUVENI, Hadas
IPC分类号: A61K31/165 , A61P35/00 , C07C327/44
CPC分类号: A61P35/00 , A61K9/08 , A61K47/40 , A61K9/0019 , A61K31/165 , A61K45/06 , C07C327/44
-
公开(公告)号:EP4400095A1
公开(公告)日:2024-07-17
申请号:EP24151951.1
申请日:2024-01-15
申请人: Hainan University
发明人: YANG, Jingjing
IPC分类号: A61K9/00 , A61K31/353 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/36 , A61K47/40 , A61P31/04 , A61P31/12 , A61P31/14
CPC分类号: A61K9/0056 , A61K31/353 , A61P31/04 , A61P31/12 , A61P31/14 , A61K9/006 , A61K47/36 , A61K47/40 , A61K47/26 , A61K47/10 , A61K47/12
摘要: The present application relates to the use of EGCG in the manufacture of a product for preventing and/or treating viral infections or bacterial infections, and also relates to a buccal tablet containing EGCG, and also relates to the use of the buccal tablet in the manufacture of a product for preventing and/or treating viral infections or bacterial infections.
-
公开(公告)号:EP4398898A1
公开(公告)日:2024-07-17
申请号:EP22868149.0
申请日:2022-09-09
IPC分类号: A61K31/33 , A61K31/435 , A61K31/40
CPC分类号: A61K31/519 , A61K9/0095 , A61K47/32 , A61K47/40
-
公开(公告)号:EP4380573A1
公开(公告)日:2024-06-12
申请号:EP21952127.5
申请日:2021-08-04
IPC分类号: A61K31/513 , A61K31/519 , A61K47/40 , A61P35/00
CPC分类号: A61K47/40 , A61K31/513 , A61P35/00 , A61K31/519 , A61K9/0019 , A61K47/10 , A61K45/06
-
公开(公告)号:EP3556371B1
公开(公告)日:2024-06-12
申请号:EP17881816.7
申请日:2017-12-13
IPC分类号: A61K9/00 , A61K9/08 , A61K47/40 , A61K47/26 , A61K47/02 , A61P3/10 , A61K31/64 , A61K47/50 , A61K9/19 , A61K47/69 , C08B37/16
CPC分类号: A61K9/08 , A61K31/64 , A61K47/02 , A61K47/26 , A61K47/40 , A61P3/10 , A61K9/0019 , A61K9/19 , A61K47/6951 , C08B37/0015
-
公开(公告)号:EP3280402B1
公开(公告)日:2024-06-05
申请号:EP16777246.6
申请日:2016-04-07
IPC分类号: A61K31/047 , A61K31/7034 , A61K31/167 , A61K31/136 , A61K31/01 , A61K31/122 , A61P17/00 , A61P29/00 , A61K31/05 , A61K31/03 , A61K31/085 , A61K31/09 , A61K31/655 , A61K9/00
CPC分类号: A61K9/0019 , A61K9/08 , A61K9/19 , A61K8/70 , A61K8/733 , A61K31/03 , A61K31/167 , A61K31/375 , A61K31/655 , A61K31/05 , A61K31/085 , A61K31/09 , A61K31/7034 , A61K45/06 , A61K9/06 , A61K47/40 , A61Q19/08 , A61Q7/00 , A61K8/347 , A61K8/33 , A61K8/602 , A61K8/738 , A61K8/676 , A61P1/04 , A61P1/16 , A61P11/06 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/14 , A61P19/02 , A61P19/06 , A61P19/10 , A61P25/00 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P3/02 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/06 , A61P43/00 , A61P7/06 , A61P9/10 , A61P3/10 , Y02A50/30
-
公开(公告)号:EP3411363A1
公开(公告)日:2018-12-12
申请号:EP16836116.0
申请日:2016-12-10
发明人: GORE, Vinayak G , SHUKLA, Vinay Kumar , SANGVIKAR, Yogesh , KOKANE, Dattatrey , GHARAT, Sushant
IPC分类号: C07D303/36 , A61K38/07 , A61K31/336 , A61K31/5375 , C07K5/10
CPC分类号: C07K5/1008 , A61K38/00 , A61K47/40 , C07B2200/13 , C07D303/36
摘要: The present disclosure provides crystalline carfilzomib form M1 and a process for the preparation thereof. Further disclosed are processes for the preparation of amorphous carfilzomib using crystalline form M1 as a starting material. The present disclosure also relates to an improved process for the preparation of carfilzomib.
-
公开(公告)号:EP3407875A1
公开(公告)日:2018-12-05
申请号:EP17744826.3
申请日:2017-01-25
发明人: MENGLER, Christopher
IPC分类号: A61K31/05 , A61K31/724
CPC分类号: A61K31/05 , A61K9/0019 , A61K9/08 , A61K31/724 , A61K47/12 , A61K47/40 , A61K2300/00
摘要: . Disclosed herein is an aqueous pharmaceutical formulation comprising about 10 mg/mL of propofol, 175 mg/mL of sulfobutylether β-cyclodextrin, a citric buffer, wherein the composition has a pH of about 5.5. Also disclosed is a method of inducing and maintaining anesthesia or sedation in a patient by administering the aqueous pharmaceutical formulation.
-
公开(公告)号:EP2945621B1
公开(公告)日:2018-10-17
申请号:EP14703010.0
申请日:2014-01-17
发明人: KALISH, Vincent Jacob , REARDON, John , BROOKFIELD, Frederick Arthur , COURTNEY, Stephen Martin , FROST, Lisa Marie , TOSCANO, John P.
IPC分类号: A61K31/18 , C07D307/64 , A61P9/04 , C07C317/14
CPC分类号: A61K31/341 , A61K9/0019 , A61K9/08 , A61K31/18 , A61K31/222 , A61K31/24 , A61K31/255 , A61K31/343 , A61K31/381 , A61K31/404 , A61K31/42 , A61K31/433 , A61K31/4436 , A61K31/5377 , A61K31/538 , A61K47/12 , A61K47/40 , C07C317/14 , C07D307/64
摘要: The disclosed subject matter provides N- substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
-
-
-
-
-
-
-
-
-